Surgical therapy is mainly indicated in stage III disease, whereas systemic medical treatment now plays a key role in stage IV melanoma.
Prof. John Kelly (The Alfred Hospital, Australia) stated that surgery for melanoma has changed . Sentinel lymph node biopsy (SLNB) is still indicated in all melanomas equal to or greater than 1 mm. However, its predictive value is limited given that 62% and 48% of patients with intermediate or thick melanomas, respectively, who have positive results will still be alive at 10 years. On the other hand, 35% of patients with thick tumours will die within 10 years after a negative result .
Surgery remains the standard of care for clinically evident stage III disease, also after neoadjuvant treatment. In stage IV, surgery is only indicated in easily resectable or imminently threatening melanoma, because stage IV is now the mainstay of systemic therapy. Surgery is used initially for brain metastases. In addition, it...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« What the future of keloid treatment could hold Next Article
Novel selective IL-23 blocker highly effective over 2 years »
Table of Contents: WCD 2019
Treating Psoriasis in 2019
Atopic Dermatitis – What is New
Dermal Reactions to Systemic Drugs
Lupus Erythematosus Today
Small Molecules – What to Expect
Optimising the Management of Keloids
Malignant Melanoma – Advances in Management
Best of the Posters
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.